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Abstract 
Background 
In recent years, the identification of peripheral biomarkers that are associated with psychiatric 
diseases, such as Major Depressive Disorder (MDD), has become relevant because these 
biomarkers may improve the efficiency of the differential diagnosis process and indicate 
targets for new antidepressant drugs. Two recent candidate genes, ErbB3 and Fgfr1, are 
growth factors whose mRNA levels have been found to be altered in the leukocytes of 
patients that are affected by bipolar disorder in a depressive state. On this basis, the aim of 
the study was to determine if ErbB3 and Fgfr1 mRNA levels could be a biomarkers of MDD. 
Methods 
We measured by Real Time PCR ErbB3 and Fgfr1 mRNA expression levels in leukocytes of 
MDD patients compared with controls. Successively, to assess whether ErbB3 mRNA levels 
were influenced by previous antidepressant treatment we stratified our patients sample in two 
cohorts, comparing drug-naive versus drug-free patients. Moreover, we evaluated the levels 
of the transcript in MDD patients after 12 weeks of antidepressant treatment, and in 
prefrontal cortex of rats stressed and treated with an antidepressant drug of the same class. 
Results 
These results showed that ErbB3 but not Fgfr1 mRNA levels were reduced in leukocytes of 
MDD patients compared to healthy subjects. Furthermore, ErbB3 levels were not affected by 
antidepressant treatment in either human or animal models 
Conclusions 
Our data suggest that ErbB3 might be considered as a biomarker for MDD and that its deficit 
may underlie the pathopsysiology of the disease and is not a consequence of treatment. 
Moreover the study supports the usefulness of leukocytes as a peripheral system for 
identifying biomarkers in psychiatric diseases. 
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Background 
Major Depressive Disorder (MDD) is a disabling psychiatric condition that is among the top 
five leading causes of disability and disease burden throughout the world [1]. MDD is a 
complex disease that is characterised by the interaction between genetic and environmental 
factors, and its hereditability, as assessed by twin and adoption studies, is approximately 40-
50% [2]. 
A biomarker is defined as a characteristic that is objectively measured and evaluated as an 
indicator of a normal biological process, a pathogenic process, or pharmacologic responses to 
a therapeutic intervention [3]. The search for MDD biological markers could be important for 
differential diagnosis, the optimisation of patient care and for the development of more 
effective drug treatments. During the past several years, research has focused on the 
identification of MDD peripheral biomarkers, supporting the idea that the neuronal alterations 
of this disabling disorder and its response to treatment might be reflected in peripheral 
biological systems such as blood [4]. 
Moreover, clinical studies have demonstrated that patients with MDD and several 
pharmacological and non-pharmacological treatments are associated with altered blood/serum 
levels of growth factors such as brain-derived neurotrophic factor (BDNF) [5,6], insulin-like 
growth factor-1 (IGF-1), vascular endothelial growth factor (VEGF) [7], glial cell line 
derived neurotrophic factor (GDNF) and fibroblast growth factor-2 (FGF-2) [4]. 
Using an approach termed convergent functional genomics (CFG), which translationally 
cross-matches animal model gene expression data with human genetic data and human tissue 
data (blood, post-mortem brain), Le-Niculescu and colleagues [8] identified a list of 
candidate blood biomarkers associated with depressive state in patients affected by bipolar 
disorder. In particular, they found five genes involved in growth factor signalling (Fgfr1, 
ErbB3, Igfbp4, Igfbp6 and Ptprm). 
Because gene expression studies on post-mortem brain tissue from depressed patients 
reported an alteration of Fgfr1 [9] and ErbB3 mRNA levels [10], and both growth factors can 
be easily measured in blood, we focussed our attention on these genes. 
Fgfr1 is a member of the fibroblast growth factor receptor (FGFR) family; these 
transmembrane catalytic receptors have intracellular tyrosine kinase activity and play 
significant roles in the development and maintenance of the central nervous system (CNS) 
[11]. Several genome-wide gene expression microarray analyses of post-mortem brain that 
were obtained from patients affected by MDD or suicide victims reported a dysregulation of 
the FGF system, suggesting a role for the FGFR family in the pathogenesis of MDD [9]. 
V-erb-b2 erythroblastic leukaemia viral oncogene homolog 3 (ErbB3) is a tyrosine kinase 
receptor, similar to ErbB2 and ErbB4, that belongs to the epidermal growth factor receptor 
(EGFR) family. EGFRs are activated by many ligands, and, on the basis of analyses of 
EGFR-deficient mice, the cell types that are most affected by the absence of EGFR are 
epithelial and glial cells [12]. Indeed, ErbB3 binds members of the neuregulin family, such as 
neuregulin 1, and plays an important role in promoting oligodendroglia differentiation [13]. 
ErbB3 and ErbB2 form homo- or heterodimers that are activated via trans-phosphorylation 
and phosphorylated. ErbB3:ErbB2 dimers provide docking sites for several factors involved 
in the initiation of cell signalling pathways, including survival, growth and transformation. In 
particular, ErbB3 is implicated in myelination processes, controlling the growth and the 
development of Schwann cells that wrap around nerve axons to provide electrical insulation 
[14]. A reduction in ErbB3 mRNA expression levels has been found in the temporal cortex of 
depressed patients [10]. 
Regarding the role of these two growth factors in antidepressant treatment, studies on animal 
models of depression indicate that the FGF system may be involved in the response to 
antidepressants [15], and there are no studies about ErbB3 in rats. 
To our knowledge, few studies have investigated biomarkers associated with MDD on 
leukocytes of drug-naive patients. Because of the antidepressant treatment is a confounding 
factor influencing the mRNA levels of several transcripts, we consider that the drug-naive 
state should be the “conditio sine qua non” to identify diagnostic biomarkers. 
Thus, the aim of this study was to assess whether (1) ErbB3 and FGFR1 mRNA levels are 
modified in MDD patient leukocytes compared to controls and (2) if their levels could be 
affected by antidepressant treatments. 
Methods 
Subjects 
A total of 26 DSM-IV MDD patients were voluntarily enrolled in the study by the Psychiatry 
Unit of IRCCS Centro S. Giovanni di Dio FBF, Brescia and by the Department of Psychiatry 
of Bolzano, Italy; all of the patients signed informed consent forms that were approved by the 
local Ethics Committee. 
Exclusion criteria were the following: a) mental retardation and cognitive disorders; b) a 
lifetime history, and a family history in first-degree relatives, of schizophrenic, 
schizoaffective, or bipolar disorders; c) personality disorders, obsessive compulsive disorder, 
post-traumatic stress disorder, as primary diagnosis; d) comorbidity with eating disorders, 
substance abuse or dependency. 
The biological sampling and clinical evaluations were performed the morning before the 
antidepressant treatment began and again after 12 weeks of treatment (T12). Blood samples 
for the expression levels at T12 were available only from 17 patients. Illness severity was 
assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS). 
The sample of 26 patients was clustered into two cohorts; the first, called the “drug-free 
group”, comprised 13 patients who had been treated previously with one of two 
antidepressants, an SSRI or TCA. For this reason, before entering in the study, each of the 
patients had a wash-out period from antidepressant drugs (only low doses of benzodiazepines 
were allowed) lasting at least 2 weeks. The second, called the “drug-naive group”, was made 
up of 13 patients who had never had previous treatment with any antidepressant drugs. 
The control sample consisted of 19 unrelated healthy volunteers that were screened for DSM-
IV Axis I disorder diagnoses using the Mini-International Neuropsychiatric Interview 
(M.I.N.I.) [16] by expert psychologists. Only healthy volunteers without a history of drug or 
alcohol abuse or dependence and without a personal or first-degree family history of 
psychiatric disorders were enrolled in the study. Moreover, an anamnestic schedule was 
compiled to assess the presence of any medical conditions or pharmacological treatment. All 
patients and controls were of Italian Caucasian origin and resided in northern Italy. Features 
of controls and MDD patients are showed in Table 1. 
Table 1 Clinical and demographical features of controls and MDD patients 
 Controls (19) MDD patients (26)  
ERBB3 mRNA levels 1.19 ± 0.74 0.67 ± 0.35 F = 9.44; p <0.01 
Age (mean ± SD) 54.63 ± 19.58 42.96 ± 8.77 F = 7.29; p = 0.01 
Gender (N;%female) 17;89% 20;77% χ2 =1.18, p = 0.28 
Education (mean ± SD) 12.7 ± 5.8 11.6 ± 2.7 F = 0.60; p = 0.43 
ErbB3 and Fgfr1 leukocyte gene expression analysis 
Two micrograms of total RNA were used for cDNA synthesis using random hexamer primers 
(Invitrogen) and Superscript II Reverse Transcriptase (Invitrogen) after assessing RNA 
quality and quantity using a NanoDrop (NanoDrop Technologies, Wilmington, DE). Real 
Time quantitative RT-PCR analyses were performed using the Step One Real Time System 
(Applied Biosystems) to determine ErbB3 and Fgfr1 mRNA levels in leukocytes. Taqman 
probes for the ErbB3 (Hs00176538_m1) and Fgfr1 (Hs00915142_m1) genes were purchased 
from Applied Biosystems. Target genes mRNA levels have been normalized on the 
arithmetic mean of β2 microglobulin (B2M; Hs99999907_m1), cytochrome c1 (Cyc1; 
Hs00357717_m1) and ATP synthase, H+ transporting mitochondrial F1 complex β subunit 
(Atpb5; Hs00969569). ErbB3 mRNA levels normalized on each housekeeping gene are 
shown in Additional file 1: Table S1. Each sample was assayed in duplicate and using two 
independent retrotranscription products. Data analyses were performed according to the 
comparative Ct method using the Applied Biosystems Real Time software, which 
automatically determines the optimal baseline and threshold settings via the auto Ct 
determination feature. 
Footshock stress procedure and drug treatments in animal models 
All experimental procedures involving animals were performed in accordance with the 
European Community Council Directive 86/609/EEC and were approved by Italian 
legislation on animal experimentation (Decreto Ministeriale 124/2003-A). Sprague–Dawley 
rats (170–200 g) were used. The footshock (FS)-stress protocol was performed essentially as 
previously reported [17] (40-min FS-stress; 0.8 mA, 20 min total of actual shock with random 
intershock length for 2–8 sec). The FS-stress box was connected to a scrambler controller 
(LE 100–26, Panlab) that delivered intermittent shocks to the metallic floor. Sham-stressed 
rats (controls) were kept in the stress apparatus without the delivery of shocks. 
Two additional groups were considered in the analysis: one group was treated chronically (14 
days) with the antidepressant escitalopram (10 mg/kg) and killed 24 h after the last injection; 
in the second group, rats were subjected to FS-stress 24 h after the last administration and 
killed 24 h thereafter. For all of the rats, the hippocampus (HPC) and the whole frontal lobe 
(referred to as prefrontal/frontal cortex (P/FC)) were quickly dissected on ice and processed. 
In rat HPC and P/FC, the expression ratio of ErbB3 (RN_00568107) in the treated groups to 
the control group was calculated using the comparative Ct method as previously described 
using β-Act (Rn00667869_m1), GAPDH (Rn_99999916_s1) and H2AFZ (Rn00821133_g1) 
transcripts as housekeeping genes. Each individual determination was repeated in duplicate. 
Statistical analysis 
Demographic and clinical characteristics in our patient and control samples were described 
either in quantitative terms of the mean ± standard deviation (SD) or as proportions. Analysis 
of variance (ANOVA) was used for computing possible differences between groups, whereas 
the chi-squared (χ2) test was used to evaluate categorical variables. The Pearson coefficient 
was used to evaluate bivariate correlations. Clinical and biological changes were analysed 
using a general linear model in a repeated measures design with time (T0, T12) as a within-
subjects factor, and the Greenhouse–Geisser correction was applied. When the data were not 
normally distributed, we used non-parametric tests. Non-parametric comparisons were made 
with the Wilcoxon signed-rank test. 
All analyses were conducted using SPSS Version 17.0 statistical software (SPSS Inc. 
Chicago, IL). 
Results 
Fgfr1 
No correlations were observed between Fgfr1 mRNA levels at baseline and age (p = 0.31), 
gender (p = 0.85), education (p = 0.16) or illness severity (p = 0.73), and no difference was 
found in Fgfr1 mRNA levels at T0 between controls and patients (1.14 ± 0.47, 1.09 ± 0.53, 
respectively; p = 0.76). There were no changes in Fgfr1 mRNA levels after 12 weeks of 
antidepressant treatment (p = 0.47), and no variations related to symptomatology (p = 0.70) 
were observed. 
ErbB3 
No correlations between T0 Erbb3 mRNA levels and age (p = 0.76; p = 0.52), gender (p = 
0.17; p = 0.47), education (p = 0.21; p = 0.32) were found in the whole cohort and in controls 
sample, respectively. A significant correlation was found with age (p = 0.004) in MDD 
patients, whereas any effects were observed with gender (p = 0.37), education (p = 0.53) and 
illness severity (p = 0.08). 
ErbB3 mRNA levels at baseline were significantly reduced in depressed patients when 
compared with controls (0.67 ± 0.35, 1.19 ± 0.74, respectively; p = 0.004; Table 1 and Figure 
1). The effect remained highly significant after adjusting by age (p = 0.001); the ANOVA 
showed that the variable age was not significant (p = 0.11) and the Partial Eta Squared Indice 
estimated the effect size was very low (p = 0.06). On the contrary the Observed Power of the 
variable group was high (p = 0.93). 
Figure 1 ErbB3 leukocytes mRNA levels in controls and MDD patients. Error bars show 
mean ± 1.0 SD. Expression levels by RT-PCR are the threshold cycle (Ct) values converted to 
RNA equivalents and then normalized to geometric mean of housekeeping genes expression 
Moreover, to evaluate whether an ErbB3 deficit could be influenced by previous 
antidepressant treatment, we stratified the samples into drug-free and drug-naïve patients. 
These analyses showed no difference in ErbB3 mRNA levels between the two groups (p = 
0.85) (Table 2). 
Table 2 Clinical and demographical features of the two cohorts of MDD patients 
 Drug-free (13) Drug-naive (13)  
ERBB3 mRNA levels 0.69 ± 0.44 0.66 ± 0.26 F = 0.04;p = 0.85 
Age (mean ± SD) 44.85 ± 9.80 41.08 ± 7.51 F = 1.21; p = 0.28 
Gender (N;%female) 12;92% 8;62% χ2 =3.47, p = 0.06 
Education (mean ± SD) 12.0 ± 2.7 11.3 ± 2.8 F = 0.40; p = 0.53 
MADRS (mean ± SD) 25.3 ± 6.3 23.3 ± 3.3 F = 1.10; p = 0.30 
According to the ANOVA, a significant symptomatology decrease occurred at T12 (MADRS 
scores p <0.001; T0 = 24.06 ± 5.98, T12 = 6.53 ± 4.58), whereas no changes in ErbB3 mRNA 
levels (p = 0.46; T0 = 0.72 ± 0.40, T12 = 0.64 ± 0.51) were found. However, ErbB3 increased 
at T12 and covaried with the amelioration of depressive symptoms (p = 0.03). A non-
parametric Wilcoxon signed rank test indicated a significant correlation between the 
expressed changes in ErbB3 mRNA levels (as Fold Change using 2
-ΔΔCT
 method) and the 
percentage of symptoms improvement (p <0.001; mean of ErbB3 changes 1.00 ± 0.76; 
ΔMADRS 72.68% ± 18.96%; Figure 2). Because two patients were outliers for the changes 
of ErbB3 we carried out the non-parametric Wilcoxon signed rank test without these two 
patients and the effect remained significant (p <0.001). 
Figure 2 Correlation between percentage of symptoms improvement ΔMADRS% and 
Fold changes in ErbB3 mRNA expression (T0-T12). FC were calculated using the 2
-ΔΔct
 
method 
ErbB3 mRNA levels in patients after 12 weeks of antidepressant treatment were still 
significantly reduced compared to T0 levels of controls (p = 0.02). However, running the 
analysis including only patients who obtained a relevant amelioration of depressive 
symptomatology (ΔMADRS >60%) the difference between patients (T12) and controls was 
lost (p = 0.17). 
Finally, no significant alteration in ErbB3 mRNA levels was observed in rat HPC or P/FC, 
after either the FS-stress protocol or/and the drug treatments (for results see Table 3). 
Table 3 ErbB3 mRNA levels in rats P/FC and HP 
 P/FC ErbB3 mRNA levels HPC ErbB3 mRNA levels 
Saline vs. Stress 1.01 ± 0.12 vs 0.94 ± 0.10; p = 0.99 1.01 ± 0.18 vs 1.04 ± 0.22 p = 0.99 
Saline vs. Escitalopram 1.01 ± 0.12 vs 0.83 ± 0.18 p = 0.17 1.01 ± 0.18 vs 1.02 ± 0.15 p = 0.99 
Saline vs. Stress + Escitalopram 1.01 ± 0.12 vs 0.90 ± 0.06 p = 0.99 1.01 ± 0.18 vs 0.93 ± 0.03 p = 0.99 
*All comparisons were adjusted for Bonferroni correction 
Discussion 
Our study has identified the involvement of ErbB3 in MDD, showing a reduction in mRNA 
levels in the leukocytes of depressed patients compared with controls, and that this deficit is 
not a consequence of antidepressant treatments. 
In accord with our study, several other studies have demonstrated that patients with MDD 
have altered blood/serum levels of growth factors and that chronic stress exposure, which can 
precipitate or exacerbate depressive episodes, alters the expression of growth factors [4]. 
By integrating human blood gene expression data, animal model expression data, human 
genetic linkage/association data and human post-mortem brain data (an approach called 
convergent functional genomics), Le-Niculescu and colleagues [8] identified a list of blood 
biomarkers of mood states in bipolar disorders. In particular, they classified the five top-
scoring candidate biomarkers for high mood (Mbp, Edg2, Fzd3, Atxn1 and Ednrb) and the 
five top-scoring candidate biomarkers for low mood (Fgfr1, Mag, Pmp22, Ugt8 and ErbB3). 
Because Fgfr1 and ErbB3 levels were also found to be altered in post-mortem brains of MDD 
patients, and their levels can be measured in blood, we investigated the association of mRNA 
leukocyte levels of these two growth factor genes with the low mood state in a cohort of 
MDD patients. 
Although we did not identify any significant changes in Fgfr1 mRNA levels in leukocytes, an 
important reduction of ErbB3 mRNA levels emerged in depressed patients, suggesting that 
ErbB3 could be considered as a biomarker of depression. Moreover, this alteration was not 
influenced by antidepressant treatments, either in humans or in animal models. 
Our findings were in agreement with Aston’s microarray data [10], which found an ErbB3 
deficit in the temporal cortex of depressed patients, supporting a role for ErbB3 in the 
pathogenesis of depression. 
Clinically, the use of peripheral biomarkers may be useful for diagnoses and in predicting 
response to drug treatment. To date, several peripheral biomarkers have been identified; 
however, some questions must be addressed before the use of biomarkers can be introduced 
into clinical practice. For MDD biomarkers, it is necessary to clarify if they correspond to a 
state of depression or a trait (constitutive). 
According to the data provided by Le-Niculescu [8] that found low ErbB3 mRNA levels in 
leukocytes of bipolar patients in a depressive state and the significant correlation we found 
between the change in the percentages of ErbB3 and change in MADRS, ErbB3 could be 
considered a biomarker of depressive status. This hyphotesis is supported also by our data 
showing that ErbB3 levels in patients who obtained a relevant amelioration of depressive 
symptomatology are not different compared to controls. We could suppose a further increase 
of ErbB3 levels when patients will be fully remitted. 
This study has some limitations. The groups were relatively small and the used samples were 
limited to leukocytes ones. Moreover, to clarify the role of ERbB3 in a low mood state, new 
studies on MDD with larger samples and in cohorts of patients with different psychiatric 
disorders in a depressive state, such as post-traumatic stress disorder (PTSD) or 
schizophrenia, are necessary. 
Conclusion 
Our results on leukocytes in humans and in animal models support the role of ErbB3 in 
depression and confirm the usefulness of leukocytes as a peripheral model for studying the 
biochemistry and molecular biology of the central nervous system. 
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